

rBCG Vaccine Trial at NICED: Request for participation

ICMR-NICED, a premier research organisation, under the Dept. of Health Research, Ministry of Health and Family Welfare, Govt. of India, is going to initiate a CDSCO approved regulatory trial entitled “A Multicentre, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM 1002 In Reducing Infection Incidence and Disease Severity of COVID-19 Among High-Risk Subjects“, Dr. Shanta Dutta, Director, ICMR-NICED being the PI of the study. The primary objective of the study is to determine the effectiveness of rBCG vaccine in reducing the incidence and disease severity of COVID-19 infection among Health Care Workers engaged in managing active COVID-19 patients. Contacts with COVID-19 cases living in containment zones of West Bengal can also participate in the study.

The Health Care Workers (doctors, nurses, paramedical staff) male or female, ≥ 18 years involved in treating COVID-19 patients in Kolkata are encouraged to participate voluntarily in this trial. Willing participants are requested to contact Dr. Suman Kanungo (9903824322) with their personal details (name, age, sex, contact number, working place and designation) sent to email (**rBCGniced@gmail.com**) for further information. Limited number of participants could be enrolled in the study and they will be screened for eligibility criteria before enrolment in the study. The last date of enrolment is **25th June 2020**.

Study site : ICMR-National Institute of Cholera & Enteric Diseases, P-33, CIT, Road, Scheme-XM, Beliaghata, Kolkata - 700010

